Figure 3.
Associations between quartile trough vedolizumab levels and proportion of patients in (A) clinical remission (Harvey-Bradshaw Index<5/partial Mayo<2); (B) biologic remission (C-reactive protein <5 mg/L plus faecal calprotectin <250 µg/g); (C) endoscopic remission (Mayo score 0/absence of inflammation and ulceration) and (D) deep remission (clinical remission plus endoscopic remission).